A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy

• Published in: Amyotrophic lateral sclerosis and frontotemporal degeneration pp. 1 - 10
• Main Authors: García-Parra, Beliu, Guiu, Josep M, Povedano, MÓnica, Modamio, Pilar
• Format: Journal Article
• Language: English
• Published: England 10-09-2024
• Subjects: Amyotrophic lateral sclerosis; gene therapy; spinal muscular atrophy; managed entry agreement; orphan drugs
• ISSN: 2167-8421; 2167-9223; 2167-9223
• DOI: 10.1080/21678421.2024.2400522

: The therapeutic options for spinal muscular atrophy (SMA) are encouraging. However, there is currently no cure for amyotrophic lateral sclerosis (ALS). The clinical and economic uncertainty surrounding innovative treatments for rare neurodegenerative diseases makes it necessary to understand managed entry agreements (MEAs). The aim of this study was to review whether models of MEAs in SMA could be extrapolated to ALS.
: We performed a scoping review with information on MEAs on SMA in Web of Science (WOS), PubMed, Lyfegen Library, the National Institute for Health and Care Excellence (NICE), and the Canadian Agency for Drugs and Technologies in Health (CADTH).
: We found 45 results in WOS and PubMed. After an initial survey, 10 were reviewed to assess eligibility, and three were selected. We obtained 44 results from Lyfegen Library, and three results each from NICE and CADTH.
: The main objective of MEAs is to reduce uncertainty in the financing of drugs with a high budgetary impact and clinical concerns, as is the case with drugs for SMA and ALS. While the information available on MEAs in SMA is scarce, some conceptual models are publicly available. MEAs for long-term treatments for SMA could be used for the design of MEAs in ALS because of their similarities in economic and clinical uncertainty.